Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1437321-24-8 | MDL No. : | MFCD28502441 |
Formula : | C31H26F2N4O6 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | FKCWHHYUMFGOPY-UHFFFAOYSA-N |
M.W : | 588.56 | Pubchem ID : | 71576419 |
Synonyms : |
RXDX-106
|
Chemical Name : | N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide |
Num. heavy atoms : | 43 |
Num. arom. heavy atoms : | 28 |
Fraction Csp3 : | 0.16 |
Num. rotatable bonds : | 9 |
Num. H-bond acceptors : | 9.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 156.11 |
TPSA : | 113.68 Ų |
GI absorption : | Low |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | Yes |
CYP2C9 inhibitor : | Yes |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | Yes |
Log Kp (skin permeation) : | -6.53 cm/s |
Log Po/w (iLOGP) : | 4.74 |
Log Po/w (XLOGP3) : | 4.73 |
Log Po/w (WLOGP) : | 6.12 |
Log Po/w (MLOGP) : | 3.29 |
Log Po/w (SILICOS-IT) : | 4.96 |
Consensus Log Po/w : | 4.77 |
Lipinski : | 1.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 1.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -6.36 |
Solubility : | 0.000259 mg/ml ; 0.00000044 mol/l |
Class : | Poorly soluble |
Log S (Ali) : | -6.85 |
Solubility : | 0.0000838 mg/ml ; 0.000000142 mol/l |
Class : | Poorly soluble |
Log S (SILICOS-IT) : | -9.76 |
Solubility : | 0.000000102 mg/ml ; 0.0000000002 mol/l |
Class : | Poorly soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 3.0 |
Synthetic accessibility : | 3.88 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Stage #1: With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 20℃; for 0.25h; Stage #2: In N,N-dimethyl-formamide at 20℃; for 12h; | 5 General procedure: Step b. N,N,N',N'-Tetramethyl-0-(7-azabenzotriazol-l-yl)uronium hexafluorophosphate (HATU) (0.072 g, 0.19 mmol) and l-ethyl-3-(4-fiuorophenyl)-2,4-dioxo-l,2,3,4- tetrahydropyrimidine-5-carboxylic acid (0.053 g,0.19 mmol) in N,N-dimethylformamide (2 mL) was added N,N-diisopropylethylamine (0.055 mL, 0.32 mmol). After 15 min stirring at rt, 4-(6,7-dimethoxyquinolin-4-yloxy)-3-fluorophenylamine (0.05 g, 0.2 mmol) was added. The reaction was stirred at rt for 12 h, diluted with EtOAc (25mL), then washed with IN Na2C03, water and brine and then dried over MgS04. The product was crystallized from MeOH to give 75 mg (68%) as a white solid, mp = 151-4 °C; LCMS m/z = 575 (M + 1); 1H NMR (DMSO) ?: 11.04 (s, 1H), 8.89 (s, 1H), 8.47 (d, 1H, J = 5.4 Hz), 7.98, 8.01 (dd, 1H, J = 2.3, 12.6 Hz), 7.52-7.56 (m, 2H), 7.33-7.46 (m, 6H), 6.47 (d, 1H, J = 5.4Hz), 4.01 (q, 2H, J = 7Hz), 3.98 (d, 6H), 13.0 (t, 3H, J = 7Hz). |